Bank of America’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-21,166
| Closed | -$31.7K | – | 8132 |
|
|
2023
Q1 | $31.7K | Sell |
21,166
-62,372
| -75% | -$84K | ﹤0.01% | 6629 |
|
|
2022
Q4 | $83.4K | Sell |
83,538
-35,129
| -30% | -$47.4K | ﹤0.01% | 6299 |
|
|
2022
Q3 | $213K | Sell |
118,667
-19,277
| -14% | -$55.9K | ﹤0.01% | 5937 |
|
|
2022
Q2 | $400K | Sell |
137,944
-77,982
| -36% | -$192K | ﹤0.01% | 5588 |
|
|
2022
Q1 | $596K | Sell |
215,926
-1,013,353
| -82% | -$3.19M | ﹤0.01% | 5702 |
|
|
2021
Q4 | $5.73M | Buy |
1,229,279
+1,132,206
| +1,166% | +$7.08M | ﹤0.01% | 3531 |
|
|
2021
Q3 | $826K | Buy |
97,073
+87,379
| +901% | +$1.23M | ﹤0.01% | 5246 |
|
|
2021
Q2 | $159K | Sell |
9,694
-6,811
| -41% | -$138K | ﹤0.01% | 6244 |
|
|
2021
Q1 | $365K | Buy |
16,505
+10,330
| +167% | +$282K | ﹤0.01% | 5622 |
|
|
2020
Q4 | $191K | Buy |
6,175
+304
| +5% | +$7.69K | ﹤0.01% | 5632 |
|
|
2020
Q3 | $119K | Sell |
5,871
-1,382
| -19% | -$24.3K | ﹤0.01% | 5598 |
|
|
2020
Q2 | $111K | Buy |
7,253
+3,773
| +108% | +$43.5K | ﹤0.01% | 5622 |
|
|
2020
Q1 | $27K | Sell |
3,480
-3,510
| -50% | -$43K | ﹤0.01% | 6081 |
|
|
2019
Q4 | $100K | Buy |
6,990
+2,550
| +57% | +$39.4K | ﹤0.01% | 5993 |
|
|
2019
Q3 | $66K | Buy |
4,440
+238
| +6% | +$3.71K | ﹤0.01% | 6215 |
|
|
2019
Q2 | $60K | Buy |
4,202
+1,849
| +79% | +$29.5K | ﹤0.01% | 6227 |
|
|
2019
Q1 | $41K | Buy |
+2,353
| New | +$41.7K | ﹤0.01% | 6272 |
|
Bank of America's TCRR Position: Q2 2023 in Review
Bank of America sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 21,166 shares — an estimated $31.7K sold.
Bank of America first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $5.73M in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Bank of America reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of America sold 21,166 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $31.7K.
- Bank of America first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Bank of America's TCR2 Therapeutics Inc. Common Stock position peaked at $5.73M in Q4 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.